PREVDUO

PAR PHARMACEUTICAL, INC.🇺🇸 United States

FDA Page

Effective Date: Feb 23, 2023
Approval ID: dd8ad38f-247b-4948-a13c-8f3a4921b4f1
Products: 1 registered
Version: 1

Regulatory Information

Labeling Type

HUMAN PRESCRIPTION DRUG LABEL

Status

Approved

Full Title

These highlights do not include all the information needed to use PREVDUO™ safely and effectively. See full prescribing information for PREVDUO™. PREVDUO™ (neostigmine methylsulfate and glycopyrrolate) injection, for intravenous use Initial U.S. Approval: 2023

Quick Stats

Total Products1

Labelers2

Label Sections16

Regulatory Agency

🇺🇸

U.S. Food and Drug Administration

United States

Data Sources & Disclaimer: Approval information is sourced from official FDA databases. This content is for informational purposes only and does not constitute medical or regulatory advice. Always refer to official FDA websites for the most current information.